165 related articles for article (PubMed ID: 31549973)
1. Stereotactic body radiation therapy and immunotherapy.
Khalife M; Shahid K; Dabney RS; Phan AT
Clin Adv Hematol Oncol; 2019 Sep; 17(9):518-523. PubMed ID: 31549973
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
3. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
Qian JM; Yu JB; Kluger HM; Chiang VL
Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
[TBL] [Abstract][Full Text] [Related]
4. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
[TBL] [Abstract][Full Text] [Related]
5. The abscopal effect associated with a systemic anti-melanoma immune response.
Stamell EF; Wolchok JD; Gnjatic S; Lee NY; Brownell I
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):293-5. PubMed ID: 22560555
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 1: Principles of Combined Treatment.
Zhang I; Formenti SC; Knisely JPS
Oncology (Williston Park); 2018 Feb; 32(2):e28-e32. PubMed ID: 29492951
[TBL] [Abstract][Full Text] [Related]
7. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 2: Existing Experience and Considerations for Future Trials.
Zhang I; Formenti SC; Knisely JPS
Oncology (Williston Park); 2018 Mar; 32(3):e33-e37. PubMed ID: 29548066
[TBL] [Abstract][Full Text] [Related]
9. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
[TBL] [Abstract][Full Text] [Related]
10. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
[TBL] [Abstract][Full Text] [Related]
12. The Abscopal Effect in the Era of Checkpoint Inhibitors.
Kodet O; Němejcova K; Strnadová K; Havlínová A; Dundr P; Krajsová I; Štork J; Smetana K; Lacina L
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281259
[TBL] [Abstract][Full Text] [Related]
13. Sustained clinico-radiologic response to anti-cytotoxic T lymphocyte antigen 4 antibody therapy in metastatic myxoid liposarcoma.
Dasanu CA
J Oncol Pharm Pract; 2017 Oct; 23(7):549-551. PubMed ID: 27511215
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced melanoma with laser immunotherapy and ipilimumab.
Naylor MF; Zhou F; Geister BV; Nordquist RE; Li X; Chen WR
J Biophotonics; 2017 May; 10(5):618-622. PubMed ID: 28417565
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Significance of Ipilimumab and the Combination Therapy as Immune Checkpoint Inhibitor].
Muto Y; Kitano S
Gan To Kagaku Ryoho; 2019 Jun; 46(6):1011-1015. PubMed ID: 31273167
[TBL] [Abstract][Full Text] [Related]
16. [Advances in immunotherapy for metastatic melanoma].
Oláh J
Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
Carreau NA; Pavlick AC
Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
[TBL] [Abstract][Full Text] [Related]
18. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
Kropp LM; De Los Santos JF; McKee SB; Conry RM
J Immunother; 2016; 39(9):373-378. PubMed ID: 27662339
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
